IDO+ DCs and signalling pathways

Current Cancer Drug Targets

Volumn 13, Issue 3, 2013, Pages 278-288

  Wang, Yue ^a   Yang, Bao Hong ^a   Li, Hui ^a   Cao, Shui ^a   Ren, Xiu Bao ^a   Yu, Jin Pu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Dendritic cells; Immune response; Indoleamine 2,3 dioxygenase; Signalling pathways; Tolerance

Indexed keywords

4 PHENYLIMIDAZOLE; B7 ANTIGEN; CARBOLINE DERIVATIVE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2, 3 DIOXYGENASE; INTERFERON REGULATORY FACTOR 3; JANUS KINASE; NAPHTHOQUINONE; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CATABOLISM; CELL PROLIFERATION; DENDRITIC CELL; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CTLA-4 ANTIGEN; DENDRITIC CELLS; ENZYME INHIBITORS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASM PROTEINS; NEOPLASMS; NF-KAPPA B; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84876843806     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990073     Document Type: Review

References (101)

1. Manicassamy, S.; Pulendran, B. Dendritic cell control of tolerogenic responses. Immunol. Rev. 2011, 241 (1), 206-227.
2. Mellor, A. L.; Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4 (10), 762-774.
3. Belladonna, M. L.; Orabona, C.; Grohmann, U.; Puccetti, P. TGFbeta and kynurenines as the key to infectious tolerance. Trends Mol. Med. 2009, 15 (2), 41-49.
4. Belladonna, M. L.; Grohmann, U.; Guidetti, P.; Volpi, C.; Bianchi, R.; Fioretti, M. C.; Schwarcz, R.; Fallarino, F.; Puccetti, P. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 2006, 177 (1), 130-137.
5. Poliani, P. L.; Kisand, K.; Marrella, V.; Ravanini, M.; Notarangelo, L. D.; Villa, A.; Peterson, P.; Facchetti, F. Human peripheral lymphoid tissues contain autoimmune regulator-expressing dendritic cells. Am. J. Pathol. 2010, 176 (3), 1104-1112.
6. Heitger, A. Regulation of expression and function of IDO in human dendritic cells. Curr. Med. Chem. 2011, 18 (15), 2222-2233.
7. Ravishankar, B.; Liu, H.; Shinde, R.; Chandler, P.; Baban, B.; Tanaka, M.; Munn, D. H.; Mellor, A. L.; Karlsson, M. C.; McGaha, T. L. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA 2012, 109 (10), 3909-3914.
8. Ino, K.; Yamamoto, E.; Shibata, K.; Kajiyama, H.; Yoshida, N.; Terauchi, M.; Nawa, A.; Nagasaka, T.; Takikawa, O.; Kikkawa, F. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin. Cancer Res. 2008, 14 (8), 2310-2317.
9. Pan, K.; Wang, H.; Chen, M. S.; Zhang, H. K.; Weng, D. S.; Zhou, J.; Huang, W.; Li, J. J.; Song, H. F.; Xia, J. C. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134 (11), 1247-1253.
10. Munn, D. H.; Mellor, A. L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007, 117 (5), 1147-1154.
11. Astigiano, S.; Morandi, B.; Costa, R.; Mastracci, L.; D'Agostino, A.; Ratto, G. B.; Melioli, G.; Frumento, G. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 2005, 7 (4), 390-396.
12. Lee, J. R.; Dalton, R. R.; Messina, J. L.; Sharma, M. D.; Smith, D. M.; Burgess, R. E.; Mazzella, F.; Antonia, S. J.; Mellor, A. L.; Munn, D. H. Pattern of recruitment of immunoregulatory antigenpresenting cells in malignant melanoma. Lab. Invest. 2003, 83 (10), 1457-1466.
13. Munn, D. H.; Sharma, M. D.; Lee, J. R.; Jhaver, K. G.; Johnson, T. S.; Keskin, D. B.; Marshall, B.; Chandler, P.; Antonia, S. J.; Burgess, R.; Slingluff, C. J.; Mellor, A. L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002, 297 (5588), 1867-1870.
14. Munn, D. H.; Sharma, M. D.; Hou, D.; Baban, B.; Lee, J. R.; Antonia, S. J.; Messina, J. L.; Chandler, P.; Koni, P. A.; Mellor, A. L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 2004, 114 (2), 280-290.
15. Ball, H. J.; Yuasa, H. J.; Austin, C. J.; Weiser, S.; Hunt, N. H. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 2009, 41 (3), 467-471.
16. Metz, R.; Duhadaway, J. B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A. J.; Prendergast, G. C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyltryptophan. Cancer Res. 2007, 67 (15), 7082-7087.
17. Lob, S.; Konigsrainer, A.; Zieker, D.; Brucher, B. L.; Rammensee, H. G.; Opelz, G.; Terness, P. IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 2009, 58 (1), 153-157.
18. Munn, D. H.; Sharma, M. D.; Baban, B.; Harding, H. P.; Zhang, Y.; Ron, D.; Mellor, A. L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22 (5), 633-642.
19. Mezrich, J. D.; Fechner, J. H.; Zhang, X.; Johnson, B. P.; Burlingham, W. J.; Bradfield, C. A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010, 185 (6), 3190-3198.
20. Liu, X.; Newton, R. C.; Friedman, S. M.; Scherle, P. A. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr. Cancer Drug Targets 2009, 9 (8), 938-952.
21. Darnell, J. J.; Kerr, I. M.; Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264 (5164), 1415-1421.
22. Chon, S. Y.; Hassanain, H. H.; Gupta, S. L. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene. J. Biol. Chem. 1996, 271 (29), 17247-17252.
23. Konan, K. V.; Taylor, M. W. Importance of the two interferonstimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J. Biol. Chem. 1996, 271 (32), 19140-19145.
24. Muller, A. J.; DuHadaway, J. B.; Donover, P. S.; Sutanto-Ward, E.; Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11 (3), 312-319.
25. Muller, A. J.; DuHadaway, J. B.; Chang, M. Y.; Ramalingam, A.; Sutanto-Ward, E.; Boulden, J.; Soler, A. P.; Mandik-Nayak, L.; Gilmour, S. K.; Prendergast, G. C. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol. Immunother. 2010, 59, (11), 1655-1663.
26. Schreiber, R. D.; Old, L. J.; Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011, 331 (6024), 1565-1570.
27. Vesely, M. D.; Kershaw, M. H.; Schreiber, R. D.; Smyth, M. J. Natural innate and adaptive immunity to cancer. Ann. Rev. Immunol. 2011, 29, 235-271.
28. Radoja, S.; Rao, T. D.; Hillman, D.; Frey, A. B. Mice bearing latestage tumors have normal functional systemic T cell responses in vitro and in vivo. J. Immunol. 2000, 164 (5), 2619-2628.
29. Mellor, A. L.; Baban, B.; Chandler, P.; Marshall, B.; Jhaver, K.; Hansen, A.; Koni, P. A.; Iwashima, M.; Munn, D. H. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 2003, 171 (4), 1652-1655.
30. Lob, S.; Konigsrainer, A.; Rammensee, H. G.; Opelz, G.; Terness, P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 2009, 9 (6), 445-452.
31. Lechner, M. G.; Liebertz, D. J.; Epstein, A. L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 2010, 185 (4), 2273-2284.
32. Martin-Gayo, E.; Sierra-Filardi, E.; Corbi, A. L.; Toribio, M. L. Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development. Blood 2010, 115 (26), 5366-5375.
33. Mellor, A. L.; Munn, D. H. Physiologic control of the functional status of Foxp3+ regulatory T cells. J. Immunol. 2011, 186 (8), 4535-4540.
34. Sharma, M. D.; Hou, D. Y.; Baban, B.; Koni, P. A.; He, Y.; Chandler, P. R.; Blazar, B. R.; Mellor, A. L.; Munn, D. H. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010, 33 (6), 942-954.
35. Jurgens, B.; Hainz, U.; Fuchs, D.; Felzmann, T.; Heitger, A. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 2009, 114 (15), 3235-3243.
36. Curti, A.; Pandolfi, S.; Valzasina, B.; Aluigi, M.; Isidori, A.; Ferri, E.; Salvestrini, V.; Bonanno, G.; Rutella, S.; Durelli, I.; Horenstein, A. L.; Fiore, F.; Massaia, M.; Colombo, M. P.; Baccarani, M.; Lemoli, R. M. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25-into CD25+ T regulatory cells. Blood 2007, 109 (7), 2871-2877.
37. Vera, J.; Rateitschak, K.; Lange, F.; Kossow, C.; Wolkenhauer, O.; Jaster, R. Systems biology of JAK-STAT signalling in human malignancies. Prog. Biophys. Mol. Biol. 2011, 106 (2), 426-434.
38. Puccetti, P. On watching the watchers: IDO and type I/II IFN. Eur. J. Immunol. 2007, 37 (4), 876-879.
39. Orabona, C.; Puccetti, P.; Vacca, C.; Bicciato, S.; Luchini, A.; Fallarino, F.; Bianchi, R.; Velardi, E.; Perruccio, K.; Velardi, A.; Bronte, V.; Fioretti, M. C.; Grohmann, U. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006, 107 (7), 2846-2854.
40. Braun, D.; Longman, R. S.; Albert, M. L. A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005, 106 (7), 2375-2381.
41. Grohmann, U.; Orabona, C.; Fallarino, F.; Vacca, C.; Calcinaro, F.; Falorni, A.; Candeloro, P.; Belladonna, M. L.; Bianchi, R.; Fioretti, M. C.; Puccetti, P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 2002, 3 (11), 1097-1101.
42. Walker, L. S.; Sansom, D. M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 2011, 11 (12), 852-863.
43. Fallarino, F.; Bianchi, R.; Orabona, C.; Vacca, C.; Belladonna, M. L.; Fioretti, M. C.; Serreze, D. V.; Grohmann, U.; Puccetti, P. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J. Exp. Med. 2004, 200 (8), 1051-1062.
44. Schultz, J.; Koczan, D.; Schmitz, U.; Ibrahim, S. M.; Pilch, D.; Landsberg, J.; Kunz, M. Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth. Clin. Exp. Metastasis 2010, 27 (3), 133-140.
45. Cheriyath, V.; Glaser, K. B.; Waring, J. F.; Baz, R.; Hussein, M. A.; Borden, E. C. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J. Clin. Invest. 2007, 117 (10), 3107-3117.
46. Hatano, H.; Kudo, Y.; Ogawa, I.; Tsunematsu, T.; Kikuchi, A.; Abiko, Y.; Takata, T. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin. Cancer Res. 2008, 14 (19), 6097-6105.
47. Cai, D.; Cao, J.; Li, Z.; Zheng, X.; Yao, Y.; Li, W.; Yuan, Z. Upregulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 2009, 9, 102.
48. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9 (11), 798-809.
49. Bromberg, J. Stat proteins and oncogenesis. J Clin Invest. 2002, 109 (9), 1139-1142.
50. Bonifazi, P.; Zelante, T.; D'Angelo, C.; De Luca, A.; Moretti, S.; Bozza, S.; Perruccio, K.; Iannitti, R. G.; Giovannini, G.; Volpi, C.; Fallarino, F.; Puccetti, P.; Romani, L. Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol. 2009, 2 (4), 362-374.
51. Correale, J.; Villa, A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann. Neurol. 2010, 67 (5), 625-638.
52. Raftery, M. J.; Wieland, D.; Gronewald, S.; Kraus, A. A.; Giese, T.; Schonrich, G. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J. Immunol. 2004, 173 (5), 3383-3391.
53. Reddy, P.; Sun, Y.; Toubai, T.; Duran-Struuck, R.; Clouthier, S. G.; Weisiger, E.; Maeda, Y.; Tawara, I.; Krijanovski, O.; Gatza, E.; Liu, C.; Malter, C.; Mascagni, P.; Dinarello, C. A.; Ferrara, J. L. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 2008, 118 (7), 2562-2573.
54. Sun, Y.; Chin, Y. E.; Weisiger, E.; Malter, C.; Tawara, I.; Toubai, T.; Gatza, E.; Mascagni, P.; Dinarello, C. A.; Reddy, P. Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 2009, 182 (10), 5899-5903.
55. Choi, S.; Reddy, P. HDAC inhibition and graft versus host disease. Mol. Med. 2011, 17 (5-6), 404-416.
56. Murray, P. J. The JAK-STAT signaling pathway: input and output integration. J. Immunol. 2007, 178 (5), 2623-2629.
57. Yang, J. W.; Ham, D. S.; Kim, H. W.; Lee, S. G.; Park, S. K.; Seo, S. K. Expression of Stat3 and indoleamine 2, 3-dioxygenase in cornea keratocytes as factor of ocular immune privilege. Graefes. Arch. Clin. Exp. Ophthalmol. 2012, 250 (1), 25-31.
58. Zhang, J.; Li, H.; Yu, J. P.; Wang, S. E.; Ren, X. B. Role of SOCS1 in tumor progression and therapeutic application. Int. J. Cancer. 2012, 130 (9), 1971-1980.
59. Palmer, D. C.; Restifo, N. P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 2009, 30 (12), 592-602.
60. Orabona, C.; Pallotta, M. T.; Volpi, C.; Fallarino, F.; Vacca, C.; Bianchi, R.; Belladonna, M. L.; Fioretti, M. C.; Grohmann, U.; Puccetti, P. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A. 2008, 105, (52), 20828-20833.
61. Yang, T.; Stark, P.; Janik, K.; Wigzell, H.; Rottenberg, M. E. SOCS-1 protects against Chlamydia pneumoniae-induced lethal inflammation but hampers effective bacterial clearance. J Immunol. 2008, 180, (6), 4040-4049.
62. Orabona, C.; Grohmann, U.; Belladonna, M. L.; Fallarino, F.; Vacca, C.; Bianchi, R.; Bozza, S.; Volpi, C.; Salomon, B. L.; Fioretti, M. C.; Romani, L.; Puccetti, P. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol. 2004, 5, (11), 1134-1142.
63. Orabona, C.; Belladonna, M. L.; Vacca, C.; Bianchi, R.; Fallarino, F.; Volpi, C.; Gizzi, S.; Fioretti, M. C.; Grohmann, U.; Puccetti, P. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol. 2005, 174, (11), 6582-6586.
64. Katz, J. B.; Muller, A. J.; Prendergast, G. C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008, 222, 206-221.
65. Perkins, N. D. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012, 12, (2), 121-132.
66. Ben-Neriah, Y.; Karin, M. Inflammation meets cancer, with NFkappaB as the matchmaker. Nat Immunol. 2011, 12, (8), 715-723.
67. Grivennikov, S. I.; Greten, F. R.; Karin, M. Immunity, inflammation, and cancer. Cell. 2010, 140, (6), 883-899.
68. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell. 2011, 144, (5), 646-674.
69. Yamaguchi, N.; Ito, T.; Azuma, S.; Ito, E.; Honma, R.; Yanagisawa, Y.; Nishikawa, A.; Kawamura, M.; Imai, J.; Watanabe, S.; Semba, K.; Inoue, J. Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 2009, 100, (9), 1668-1674.
70. Nishina, T.; Yamaguchi, N.; Gohda, J.; Semba, K.; Inoue, J. NIK is involved in constitutive activation of the alternative NF-kappaB pathway and proliferation of pancreatic cancer cells. Biochem Biophys Res Commun. 2009, 388, (1), 96-101.
71. Keats, J. J.; Fonseca, R.; Chesi, M.; Schop, R.; Baker, A.; Chng, W. J.; Van Wier, S.; Tiedemann, R.; Shi, C. X.; Sebag, M.; Braggio, E.; Henry, T.; Zhu, Y. X.; Fogle, H.; Price-Troska, T.; Ahmann, G.; Mancini, C.; Brents, L. A.; Kumar, S.; Greipp, P.; Dispenzieri, A.; Bryant, B.; Mulligan, G.; Bruhn, L.; Barrett, M.; Valdez, R.; Trent, J.; Stewart, A. K.; Carpten, J.; Bergsagel, P. L. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007, 12, (2), 131-144.
72. Puccetti, P.; Grohmann, U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007, 7, (10), 817-823.
73. Onodera, T.; Jang, M. H.; Guo, Z.; Yamasaki, M.; Hirata, T.; Bai, Z.; Tsuji, N. M.; Nagakubo, D.; Yoshie, O.; Sakaguchi, S.; Takikawa, O.; Miyasaka, M. Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions. J Immunol. 2009, 183, (9), 5608-5614.
74. Friedline, R. H.; Brown, D. S.; Nguyen, H.; Kornfeld, H.; Lee, J.; Zhang, Y.; Appleby, M.; Der SD; Kang, J.; Chambers, C. A. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med. 2009, 206, (2), 421-434.
75. Wingender, G.; Garbi, N.; Schumak, B.; Jungerkes, F.; Endl, E.; von Bubnoff, D.; Steitz, J.; Striegler, J.; Moldenhauer, G.; Tuting, T.; Heit, A.; Huster, K. M.; Takikawa, O.; Akira, S.; Busch, D. H.; Wagner, H.; Hammerling, G. J.; Knolle, P. A.; Limmer, A. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol. 2006, 36, (1), 12-20.
76. Hryniewicz, A.; Boasso, A.; Edghill-Smith, Y.; Vaccari, M.; Fuchs, D.; Venzon, D.; Nacsa, J.; Betts, M. R.; Tsai, W. P.; Heraud, J. M.; Beer, B.; Blanset, D.; Chougnet, C.; Lowy, I.; Shearer, G. M.; Franchini, G. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood. 2006, 108, (12), 3834-3842.
77. Comin-Anduix, B.; Lee, Y.; Jalil, J.; Algazi, A.; de la Rocha, P.; Camacho, L. H.; Bozon, V. A.; Bulanhagui, C. A.; Seja, E.; Villanueva, A.; Straatsma, B. R.; Gualberto, A.; Economou, J. S.; Glaspy, J. A.; Gomez-Navarro, J.; Ribas, A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J. Transl. Med. 2008, 6, 22.
78. Ribas, A.; Comin-Anduix, B.; Economou, J. S.; Donahue, T. R.; de la Rocha, P.; Morris, L. F.; Jalil, J.; Dissette, V. B.; Shintaku, I. P.; Glaspy, J. A.; Gomez-Navarro, J.; Cochran, A. J. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res. 2009, 15 (1), 390-399.
79. Quezada, S. A.; Peggs, K. S.; Curran, M. A.; Allison, J. P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006, 116 (7), 1935-1945.
80. Kavanagh, B.; O'Brien, S.; Lee, D.; Hou, Y.; Weinberg, V.; Rini, B.; Allison, J. P.; Small, E. J.; Fong, L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dosedependent fashion. Blood 2008, 112 (4), 1175-1183.
81. Belladonna, M. L.; Volpi, C.; Bianchi, R.; Vacca, C.; Orabona, C.; Pallotta, M. T.; Boon, L.; Gizzi, S.; Fioretti, M. C.; Grohmann, U.; Puccetti, P. Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 2008, 181 (8), 5194-5198.
82. Cook, C. H.; Bickerstaff, A. A.; Wang, J. J.; Nadasdy, T.; Della, P. P.; Colvin, R. B.; Orosz, C. G. Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO. J. Immunol. 2008, 180 (5), 3103-3112.
83. Laouar, Y.; Town, T.; Jeng, D.; Tran, E.; Wan, Y.; Kuchroo, V. K.; Flavell, R. A. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2008, 105 (31), 10865-10870.
84. Andersson, J.; Tran, D. Q.; Pesu, M.; Davidson, T. S.; Ramsey, H.; O'Shea, J. J.; Shevach, E. M. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J. Exp. Med. 2008, 205 (9), 1975-1981.
85. Chen, W. IDO: more than an enzyme. Nat. Immunol. 2011, 12 (9), 809-811.
86. Pallotta, M. T.; Orabona, C.; Volpi, C.; Vacca, C.; Belladonna, M. L.; Bianchi, R.; Servillo, G.; Brunacci, C.; Calvitti, M.; Bicciato, S.; Mazza, E. M.; Boon, L.; Grassi, F.; Fioretti, M. C.; Fallarino, F.; Puccetti, P.; Grohmann, U. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 2011, 12 (9), 870-878.
87. Bonifazi, P.; D'Angelo, C.; Zagarella, S.; Zelante, T.; Bozza, S.; De Luca, A.; Giovannini, G.; Moretti, S.; Iannitti, R. G.; Fallarino, F.; Carvalho, A.; Cunha, C.; Bistoni, F.; Romani, L. Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis. Mucosal Immunol. 2010, 3 (2), 193-205.
88. Medzhitov, R.; Shevach, E. M.; Trinchieri, G.; Mellor, A. L.; Munn, D. H.; Gordon, S.; Libby, P.; Hansson, G. K.; Shortman, K.; Dong, C.; Gabrilovich, D.; Gabrysova, L.; Howes, A.; O'Garra, A. Highlights of 10 years of immunology in Nature Reviews Immunology. Nat. Rev. Immunol. 2011, 11 (10), 693-702.
89. Lancellotti, S.; Novarese, L.; De Cristofaro, R. Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors. Curr. Med. Chem. 2011, 18 (15), 2205-2214.
90. Macchiarulo, A.; Camaioni, E.; Nuti, R.; Pellicciari, R. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids 2009, 37 (2), 219-229.
91. Opitz, C. A.; Litzenburger, U. M.; Opitz, U.; Sahm, F.; Ochs, K.; Lutz, C.; Wick, W.; Platten, M. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One 2011, 6 (5), e19823.
92. Yue, E. W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K. J.; Hansbury, M. J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T. C.; Koblish, H. K.; Fridman, J. S.; Metcalf, B.; Scherle, P. A.; Combs, A. P. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J. Med. Chem. 2009, 52 (23), 7364-7367.
93. Okamoto, T.; Tone, S.; Kanouchi, H.; Miyawaki, C.; Ono, S.; Minatogawa, Y. Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue: Downregulation of the indoleamine 2,3-dioxygenase (IDO) transcription by tryptophan and its analogue. Cytotechnology 2007, 54 (2), 107-113.
94. Eguchi, N.; Watanabe, Y.; Kawanishi, K.; Hashimoto, Y.; Hayaishi, O. Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives. Arch. Biochem. Biophys. 1984, 232 (2), 602-609.
95. Kumar, S.; Malachowski, W. P.; DuHadaway, J. B.; LaLonde, J. M.; Carroll, P. J.; Jaller, D.; Metz, R.; Prendergast, G. C.; Muller, A. J. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J. Med. Chem. 2008, 51 (6), 1706-1718.
96. Gaspari, P.; Banerjee, T.; Malachowski, W. P.; Muller, A. J.; Prendergast, G. C.; DuHadaway, J.; Bennett, S.; Donovan, A. M. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J. Med. Chem. 2006, 49 (2), 684-692.
97. Banerjee, T.; Duhadaway, J. B.; Gaspari, P.; Sutanto-Ward, E.; Munn, D. H.; Mellor, A. L.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008, 27 (20), 2851-2857.
98. Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J. M.; DuHadaway, J. B.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J. Med. Chem. 2008, 51 (16), 4968-4977.
99. Sono, M.; Cady, S. G. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. Biochemistry 1989, 28 (13), 5392-5399.
100. Brastianos, H. C.; Vottero, E.; Patrick, B. O.; Van Soest, R.; Matainaho, T.; Mauk, A. G.; Andersen, R. J. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J. Am. Chem. Soc. 2006, 128 (50), 16046-16047.
101. Vottero, E.; Balgi, A.; Woods, K.; Tugendreich, S.; Melese, T.; Andersen, R. J.; Mauk, A. G.; Roberge, M. Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. Biotechnol. J. 2006, 1 (3), 282-288.